logo
Share SHARE
FONT-SIZE Plus   Neg

Celgene Reveals Multiple Analyses Data Of Abraxane In Non-Small Cell Lung Cancer

Celgene International Sarl, a subsidiary of Celgene Corp. (CELG), Sunday revealed data from multiple presentations evaluating Abraxane in combination with carboplatin in patients with advanced non-small cell lung cancer.

The two reports presented data from retrospective analyses of CA-031, the phase III, multi-center, randomized study where patients received either nab-paclitaxel weekly plus carboplatin every three weeks or paclitaxel every three weeks plus carboplatin as first-line therapy for advanced non-small cell lung cancer.

Based on the data from CA-031, Celgene submitted an sNDA for Abraxane for the first-line treatment of patients with advanced non-small cell lung cancer with the U.S. Food and Drug Administration in December 2011. The current PDUFA (Prescription Drug User Fee Act) date for the submission is October 12, 2012.

Results of the study published on April 30, 2012 in the Journal of Clinical Oncology demonstrated a higher overall response rate, the approved primary end-point of the study based on a Special Protocol Assessment, for patients in the nab-paclitaxel arm compared to those in the paclitaxel arm.

The first sub-analysis evaluated elderly patients in the study and patients under 70. In both groups, overall response rate was higher in patients receiving nab-paclitaxel, though the difference was not significant in elderly patients between the arms of the study.

The second report evaluated patients with squamous-cell histology and non-squamous cell patients. The nab-paclitaxel arm demonstrated a significantly higher overall response rate and a slight improvement in overall survival, compared to the paclitaxel arm.

These results are from an investigational study and Abraxane is not indicated in the treatment of non-small cell lung cancer.

CELG traded on Friday at $65.33, down $2.92 or 4.28%, on a volume of 4.5 million shares on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Maternity leave is a temporary period of absence from employment granted to expectant or new mothers during the months immediately before and after their pregnancy. Parental leave, including maternity, paternity and adoption leave, is an employee benefit. Many countries around the world, including... Texas, the second largest state in the U.S., has four of the five fastest-growing cities in the U.S., according to new population estimates released Thursday by the U.S. Census Bureau for the twelve months up to July 1, 2016. Ten of the fifteen fastest growing large U.S. cities during that 12-month span were in the South, according to the Census Bureau. To book-lover's surprise, online retailer Amazon opened another bricks and mortar store in an upmarket shopping mall in New York. This is the seventh book store of Amazon.
comments powered by Disqus
Follow RTT